Bendamustine + Rituximab
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma, Indolent Non-hodgkin Lymphoma
Trial Timeline
Jun 1, 2025 → Mar 30, 2028
NCT ID
NCT06557330About Bendamustine + Rituximab
Bendamustine + Rituximab is a phase 2 stage product being developed by Adaptive Biotechnologies for Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06557330. Target conditions include Lymphoma, Indolent Non-hodgkin Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06557330 | Phase 2 | Recruiting |
Competing Products
20 competing products in Lymphoma